With increased automation and larger compound collections, the development of highthroughput screening (HTS) started replacing previous approaches in drug discovery from around the 1980s onwards. However, even today it is not always appropriate, or even feasible, to screen large collections of compounds in a particular assay. Here, we present an efficient method for iterative screening of small subsets of compound libraries. With this method the retrieval of active compounds is optimized using their structural information and biological activity fingerprints. We validated this approach retrospectively on 34 Novartis in-house HTS assays covering a wide range of assay biology, including cell proliferation, antibacterial activity, gene expression and phosphorylation. This method was employed to retrieve subsets of compounds for screening, where selected hits from any given round of screening were used as starting points to select chemically and biologically similar compounds for the next iteration. By only screening ~1% of the full screening collection (~15,000 compounds), the method consistently retrieves diverse compounds belonging to the top 0.5% most active compounds for the HTS campaign.
INTRODUCTION
Early drug discovery traditionally has been the result of a close collaboration between chemists, pharmacologists and clinical scientists, where knowledge from pharmacology and (medicinal) chemistry was combined to design potentially active molecules for testing. 1, 2 From around the 1980s onwards rapid improvements in automation and combinatorial chemistry led to the development and increasing acceptance of high-throughput screening (HTS), which allows rapid screening of large collections of compounds using robotics and automated data processing. This allowed enabled HTS to be used to study relationships between compounds and putative biological targets on a very large scale, so that libraries of 1-2 million compounds are routinely screened in big pharmaceutical companies, several times per year. 2, 3 Conceptually, HTS aims to screen large numbers of molecules in a brute-force approach to identify hits, and the most promising chemical entities are then selected as starting points for further investigation. It is hoped thatThe rationale behind screening large numbers of molecules is that it increases the chances of finding promising chemical entities. However, the previous often iterative cycles of design-screen-refine in small interdisciplinary project teams were somewhat lost.
Over the last few decades, HTS has hence become increasingly popular and has increased augmented in capacity from being able to screen tens of thousands of compounds a day to over 100,000 compounds a day, and has become -besides many other techniques -of crucial importance for early drug discovery. [4] [5] [6] However, HTS also has some significant drawbacks.
Cell-free HTS campaigns, such as biochemical target-based assays, are not adequately predictive of compounds' ADMET (absorption, distribution, metabolism, excretion and toxicity) properties which are important pharmacokinetic parameters for drug development. 7 For cell-based phenotypic HTS assays, which can be more predictive of certain ADMET properties such as bioavailability and cytotoxicity, target deconvolution is an important challenge. 8 Additionally,
HTS campaigns sometimes cannot be performed at scale for complex biological systems that cannot be mass-produced (e.g. organoids). 9 Finally, and of most relevance for the current study, HTS remains a resource-intensive endeavor with a large fraction of the compounds screened being inactive or uninteresting. The latter renders the identification of smaller screening sets which lead to a significant fraction of active chemical matter detected very relevant. 4 The mentioned drawbacks prompted efforts to optimize various aspects of HTS campaigns, such as compound library design (for example, based on chemical diversity, where libraries are chosen on the basis of chemical knowledge), [10] [11] [12] [13] [14] post-HTS data analysis for triaging active compounds (in order to select subsets for further validation) 15, 16 and selecting novel compounds similar to active compounds detected in the assay for further investigation. [17] [18] [19] [20] [21] individual molecules, where molecules are designed automatically using evolutionary algorithms and particle swarm optimization. 26 However, our approach differs considerably, because we iteratively generate sets of molecules instead of individual molecules, hence investigating the concept on a much larger scale.
METHODS

HTS data
Novartis proprietary HTS assays comprising at least 1,300,000 compounds with an inhibitory assay readout were used, resulting in a total of 34 assays, of which 11 were cell-based assays and 23 were cell-free (biochemical) assays. These assays covered a wide number of biological events, including cell proliferation, antibacterial activity, gene expression and phosphorylation (Supplementary Table S1 ).
Starting set for initial screening round
We used a starting set of well-studied and manually curated compounds, many with tested clinical relevance, known to cover a large amount of druggable bioactivity space and of which the mechanism of action (MoA) is known. This set (the MoABox) comprised 2,757 compounds and is used as a starting point for many phenotypic screening projects at Novartis due to the high-quality annotations of each compound. The physicochemical properties and the chemical and biological diversity of the MoABox were calculated using RDKit 27 (Supplementary Figures   S1 and S2 ). The design of the MoABox inherently entails that most compounds have properties favorable for cell-based screening. Owing to operational turnover of the compound archive, not every full-deck HTS contains every compound of the MoABox. Therefore, the starting set for each specific assay was the MoABox compounds present in it at the time it was performed. The smallest starting set comprised 2,050 compounds, whereas the largest comprised 2,692 compounds.
In order to determine the importance of the starting set for good performance, we repeated our analysis with 10 randomly chosen starting sets and the results were compared to those obtained with the MoABox as starting set. These sets were obtained by repeatedly selecting a random subset from the entire screening deck of equal size to that of the MoABox present in the corresponding assay, minus any MoABox compounds that might have been coincidentally selected.
Iterative screening algorithm (ISA)
For any given set of compounds we are able to look up its activities in a past assay with ~1.3M
compounds. This in silico screening allows not only a relative ranking (according to activities within the subset) but also an absolute ranking (according to the 1.3M compounds). Our aim was to iteratively optimize the absolute ranking of subsets of compounds, thereby efficiently selecting highly active compounds and steering the screening process towards success with much smaller compound sets. Therefore, the method developed in this study consists of three iterative procedures (see Figure 1 ): (1) ranking of compounds based on retrospective activity data, (2) selection/triaging of hits (3) expanding from hits to close analogs based on chemical and biological similarity metrics. Since this study is a retrospective analysis on HTS data, the ranks of the compounds selected correspond to the ranks of the same compounds had they been screened in a full-deck screen. Our method is fundamentally different from a basic similarity search using active probes, because we perform a similarity search iteratively based on active compound information at every round of screening, rather than only once. Circular fingerprints 28 (SciTegic ECFP4-like) were used as features for determining chemical similarity and HTSfingerprints (HTS-FP) 23 were used as features for determining biological similarity.
Metrics used for performance assessment
We used two criteria for evaluating compound sets at each iteration: (1) the rank distribution based on compound activity and (2) the cumulative coverage of Murcko scaffolds 29 found in the top 0.5% of compounds ranked by activity. In conjunction, these criteria assess the retrieval of not only active, but also structurally diverse sets of compounds. In the below, a median rank cutoff of 65,000 is sometimes used to assess performance; this corresponds to 5% of a total screening collection of 1.3 million compounds.
Systematic exploration of parameters
The number of compounds triaged per iteration as well as the number and types of expansions affect the size and diversity of the compound sets selected. First, the number of top-performing compounds triaged can be varied. Second, expansions can be adjusted (chemical and/or biological similarity), as well as the corresponding Tanimoto 30 similarity cut-off and maximum number of expansions per compound. Moreover, the maximum number of compounds originating from the same parent compound can be adjusted in order to limit the number of closely related analogs. We systematically explored the influence of these parameters in a number of in silico experiments (see Table 1 
Data analysis
The workflow comprised Python and Perl scripts for data analysis, the Indigo toolkit 31 and RDKit 27 for cheminformatics calculations. Spotfire 32 was used for data exploration and R 33 and Cytoscape 34 were used for the visualization of results.
RESULTS AND DISCUSSION
Here we present in detail the results belonging to the reference experiment, followed by a comparison to other experiments. Experiments 4, 6 and 7 showed the same results as the reference experiment and are therefore not discussed separately; these experiments highlight,
however, that more than 50 expansions or a more stringent HTS-FP similarity cut-off do not change the results.
Iterative screening is highly effective across assay types
The median rank of the compounds selected was 36,101 (excluding the starting set) across all assay types, which corresponds to the top ~2.8% of a collection of ~1.3M compounds. In other words, half the compounds selected across all iterations (except for the starting set) are found among the top 2.8% of the corresponding 1.3M compound screen, indicating a clear enrichment in activity of the compounds selected. Of note, the performance is consistent for a large number of different assay types (median rank below 65,000, see Figure 2 ). However, for the types enzyme activity/cleavage assay, protein cleavage assay, protein functional assay and proteinprotein binding assay the performance was reduced, as evidenced by a median rank greater than 65,000 combined with a higher standard deviation.
Interestingly, performance is better for the cell-free assays than the cell-based assays (rank distributions for both assay formats is shown in Figure 3 ). In order to investigate whether this difference was statistically significant, a paired t-test was performed for the median ranks across iterations 1 to 10. In addition, a Kolmogorov-Smirnov test was performed for every iteration on compound ranks of different assay formats. All p-values were smaller than 10 -5 , hence indicating a statistically significant difference in distribution of rank between cell-free and cell-based assays. This difference is likely due to the fact that in order for compounds to have an effect in cell-based assays, they have to be able to cross the cell membrane to reach the target of interest (in cases when this target is not membrane-bound). Hence, these compounds must have suitable physicochemical properties (such as permeability), in order to be effective. Since our method on purpose did not distinguish between cell-free and cell-based assays, these results are in line with expectations; however, specific compound criteria for cell-based assays (e.g. incorporation of logP values, past performance in cell-based assays) are likely to diminish this observed gap in performance between the two assay formats in the future. As mentioned before, the MoAbox content is geared towards hypothesis-generating cell-based phenotypic screening; as a result, this set of compounds performs equally well on cell-based and cell-free assays ( Figure 3 , iteration 0).
Next, median compound ranks were evaluated per assay type ( Figure 4 ). The iterative method performs consistently well for the majority of assay types (median ranks are smaller than 100,000 for iterations 1-10 for 11 out of the 16 assay types), but there are a number of outlier assay types for which the median rank of compounds selected swiftly deteriorates after around iteration 3. These assays cover the biological events protein-protein binding, protein cleavage, protein function and enzyme activity/cleavage, and are the same ones shown to have an overall median rank above 65,000 ( Figure 2 ). These results suggest that expansions in chemical and biological space are unable to effectively retrieve the most active compounds for these assay types after the first few iterations.
Chemical diversity analysis of iterative screening results
In addition to the rank distribution of the iteratively selected compounds, we also analyzed the percentage of highly active scaffolds cumulatively retrieved. Highly active scaffolds were separately defined for each assay as the Murcko scaffolds 29 Figure S3 , where scaffold 1 is the second most commonly retrieved scaffold, corresponding to a prevalence of 1.4% in the compounds screened for all assays in iterations 1 to 10. These results indicate that our method is able to prioritize diverse chemical matter despite much smaller screening sets. In addition, it performs substantially better than a traditional similarity search as the retrieval of highly active scaffolds is only 11% in the first iteration where the similarity search would stop, compared to 41% after 10 rounds of iterative screening.
The percentage of cumulatively retrieved highly active scaffolds steadily increases with the iteration count ( Figure 5 ), with the steepest increases occurring in the earliest iterations. Most assay types display a scaffold retrieval of ~30-45% after 10 iterations. The calcium quantification assay showed relatively poor scaffold coverage (~20% after 10 iterations), whereas the phosphorylation assay, typically used for kinase inhibitors, showed much better scaffold coverage compared to other assay types (~55% after 10 iterations). Given the presence of many series of high-quality kinase inhibitors from past drug discovery programs in the Novartis screening archive, in combination with the promiscuity of kinase inhibitor binding, 35, 36 it is likely that many active inhibitors retrieved are structurally/biologically similar. Hence, this is a possible explanation for the preferred retrieval of a higher number of active scaffolds for phosphorylation assays. Another interesting observation is that the assays for protein-protein binding, protein cleavage and enzyme activity show mediocre median ranks (>65,000), while having average scaffold retrieval rates (30-40% retrieval after 10 iterations). This suggests that while our ISA is able to retrieve many compounds present in the top 0.5% of most active compounds (to an extent comparable with the majority of other assays), many inactive compounds are retrieved as well, resulting in a higher standard deviation in rank (see Figure 2 ).
The hypothetically best scaffold retrieval among the top 0.5% of compounds screened would be achieved by sorting the top 0.5% of compounds by activity and picking their scaffolds. The comparison between the hypothetically best scaffold retrieval and iterative scaffold retrieval rate is shown in Supplementary Figure S4 . For example, after picking 5,000 compounds this best possible performance retrieves ~75% of highly active scaffolds, compared to ~10-25% of highly active scaffolds (depending on assay type) retrieved iteratively and ~0.4% that would be retrieved if selection was random. In other words, iterative screening of ~15,000 compounds recovers a third of the structural diversity of the top 5,000 compounds of a 1.3M compound screen.
The fraction of highly active scaffolds retrieved was also analyzed across all assay types. Here, we determined the fraction of highly active scaffolds for each iteration (see Figure 6 ). We observed that, in general, the active scaffolds which are easily identified are quickly retrieved:
for the first few iterations the fraction of highly active scaffolds retrieved sharply increases from ~10% to ~30-80%, after which it slowly decreases, indicating the progressive difficulty in finding the remaining highly active scaffolds. A possible explanation is the presence of unreachable singletons in the screening archive that are beyond the expansions we implemented thus far.
Visualization of stepwise exploration of chemical space
In order to illustrate the iterative compound selection in more detail, we showed the expansions for an inhibitory cell-free kinase assay in a network graph (see Figure 7 ). All compounds from the starting set (0 th iteration) leading to no further expansions have been omitted from the network graph, whereas those that lead to at least one further expansion are depicted on the large 
Tuning iterative screening to assay requirements
The number of compounds triaged per iteration has a large effect: as more compounds are carried forward, both the median ranks and the scaffold retrieval for compounds selected in When investigating the dependence of scaffold coverage on fingerprint type, we found that HTS-FP-based and structure-based expansions accounted for 90% and 50%, respectively, of total highly active scaffold retrieval after 10 iterations (Supplementary Figure S7) . Since HTS-FPs capture the biological profile of compounds, HTS-FP similarity leads to more structurally diverse sets of biologically similar compounds compared to structure-based expansions.
Increasing the Tanimoto 30 cut-off from 0.6 to 0.8 (comparison of experiment 5 to the reference experiment) for structure-based expansions decreased both median compound ranks from 36,101 to 16,831 (paired t-test p-value of 9.410 -4 ) and scaffold retrieval from 28% to 16% (paired t-test p-value of 2.610 -6 ). The maximum number of compounds triaged per parent compound did not have a clear effect on the diversity nor the ranks of the compounds screened. Lowering this number from 5 (reference experiment) to 2 (experiment 8) resulted in a 2% higher scaffold retrieval (paired t-test p-value of 0.047), whereas an increase to 10 (experiment 9) had no significant effect on either median ranks or scaffold retrieval. In summary, the number of compounds triaged was the most influential factor, which can be adjusted depending on the number of compounds one intends (or can afford) to screen.
Finally, iterative screening was repeated with 10 randomly chosen starting sets and the results were compared to those obtained with the MoABox as starting set. The latter resulted in better median ranks only until the first iteration and virtually identical median ranks from iteration two onwards, and slightly higher scaffold retrieval throughout all iterations (Supplementary Figure   S8 ). While minor differences across starting sets can be observed, the key findings presented in this study are independent of the precise composition of the starting set. However, availability of a high-quality starting set, as the MoAbox for us, can provide biological insight early on through comprehensive compound annotations.
CONCLUSION
Even though alluded to in the literature and theoretically appealing, no comprehensive practical evaluation of iterative screening was published. In this study We we have performed an unequalled large-scale validation of iterative screening on 34 HTS assays comprising at least 1,300,000 compounds and showed greatly improved efficiency over conventional HTS campaigns. For most assays, half of the compounds found by iterative screening of only 1%
(~15,000 compounds) of the entire collection correspond to the top 5% of the full collection screen. Put differently, screening only 1% of the collection provides ~7,500 top-quality hits for further optimization. On average, the compounds selected covered over 40% of the scaffolds belonging to the top 0.5% most active compounds for each assay, hence also ensuring structural diversity. Our method allows for exit points during the iterative screening process: performing large numbers of iterations is not necessary in order to retrieve active compounds, as they are retrieved starting from the 1 st iteration already, and therefore, a large investment in resources upfront is not required. As expected, the method in its current state performs better for cell-free assays compared to cell-based assays; a future improvement can gear towards physicochemical properties more adapted to cell-based screens.
We used network graphs to visualize the compound selection process, and to highlight activity cliffs, 37 scaffold hopping and the effect of changing the number of compounds triaged (which was found to have the largest influence on compound selection). As an outlook for further refinement of our method, we propose (1) investigating activity cliffs 37 (to be able to prioritize expansion types) and (2) employing iteratively-retrained machine-learning methods 20 to rank the screening collection in parallel to the structure-based and HTS-FP-based expansions currently performed. We believe that the iterative method developed here can easily be fine-tuned for specific assay types, provides multiple exit points and can potentially lead to considerable savings in both time and resources. The ISA performs consistently well for most assay types, but there are a number of assays for which the median rank of compounds selected swiftly deteriorates after around iteration 3. These assays are for protein-protein binding, protein cleavage, protein function and enzyme activity/cleavage, and are the same ones
shown to have an overall median rank greater than 65,000 ( Figure 2 ).
Figure 5. Cumulatively retrieved highly active scaffolds (%).
For all assay types, the percentage of cumulatively retrieved highly active scaffolds (scaffolds of the 0.5% most active compounds of the full HTS) steadily increases, with the steepest increases occurring in the earliest iterations. Most assay types display a scaffold retrieval of between ~30-45% after 10 iterations. The calcium quantification assay showed relatively poor scaffold coverage (~20% after 10 iterations), whereas the phosphorylation assay showed much better scaffold coverage compared to other assay types (~55% after 10 iterations).
Figure 6. Fraction of highly active scaffolds retrieved (%).
The ISA exhibits a general trend for all assays: for the first 2 or 3 iterations the fraction of highly active scaffolds retrieved per iteration sharply increases from ~10% to 30-80% depending on assay type (the active scaffolds which are easy to identify are quickly retrieved), after which it slowly decreases, as it becomes increasingly difficult to find the remaining highly active scaffolds. Nevertheless, active scaffolds are still retrieved at the last iterations.
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Worse ranking HTS-FP activity cliff (bold and wide edge) increases, the median ranks consistently increase for iterations 1 to 10, whereas scaffold retrieval is higher as well.
These results are in accordance with our expectations: as the number of triaged compounds is increased (i.e. a less Tables section Table 1 
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Supplementary Figure S3 . Examples of commonly retrieved scaffolds for iterations 1-10 for all assay types.
While the scaffolds are not rank ordered according to their prevalence (for example, many scaffolds with a prevalence higher than 0.14% are not shown in the figure), scaffold 1 is the second most commonly retrieved Supplementary Figure S4 . Cumulatively retrieved highly active scaffolds (%) for all assay types compared to the "best possible performance". The gray area represents the 95% confidence interval for the corresponding assay type based on a linear model. When the "best possible performance" retrieves ~75% of highly active scaffolds, the ISA retrieves approximately ~10-25% of highly active scaffolds (depending on assay type).
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Supplementary Figure S5 . Effect of varying the number of compounds triaged per iteration in terms of the fraction of highly active scaffolds retrieved (%). As more compounds are triaged, more compound expansions take place and more compounds are screened overall. As a consequence, the fraction of highly active scaffolds retrieved for every iteration decreases consistently.
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Supplementary Figure S6 . Illustration of the effect of varying the number of compounds triaged per iteration using networks for an inhibitory cell-free kinase assay. As more compounds are triaged, more compound expansions take place and more compounds are screened overall. For example, the compounds belonging to the subnetwork in the lower-right corner of the figure can be found by the algorithm by triaging 100 or more compounds per iteration (these compounds are not found in case only 50 compounds are triaged per iteration).
